Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 envelope glycoprotein gp120 V3 loop (third variable loop) is a critical region of the viral envelope spike that plays a pivotal role in viral entry and pathogenesis. It is responsible for determining viral tropism by interacting with host cell co-receptors, primarily CCR5 or CXCR4, following the initial binding of gp120 to the CD4 receptor. Because of its essential role in infection, the V3 loop is a major target for the host humoral immune response and is often referred to as the principal neutralizing determinant of HIV-1. However, the high sequence variability of this region and its conformational occlusion within the pre-fusion envelope trimer present significant challenges for vaccine design and therapeutic targeting.
In recent years, the discovery of second-generation broadly neutralizing antibodies (bNAbs) has revitalized interest in the V3 loop as a therapeutic target. These bNAbs, such as zinlirvimab (10-1074-LS) and PGT121, target conserved peptide motifs and associated glycans (such as the N332 glycan supersite) at the base of the V3 loop. By binding to these sites, the antibodies prevent the conformational changes required for co-receptor engagement, thereby blocking viral entry into host CD4+ T cells. Clinical development of these bNAbs, often in combination with other long-acting antiretrovirals like lenacapavir, represents a promising strategy for long-acting HIV-1 treatment and prevention.
Broadly neutralizing antibodies (bNAbs) bind to the V3 loop or its associated glycans (such as the N332 glycan supersite) on the HIV-1 gp120 envelope glycoprotein. This binding physically blocks the interaction of gp120 with host cell co-receptors (CCR5 or CXCR4) and prevents viral entry and fusion into host CD4+ T cells.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 envelope glycoprotein gp120 V3 loop (gp120 V3 loop).